NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of the Company's issued and outstanding common shares. At a Special Meeting of Stockholders held on April 16, 2025, shareholders approved a special resolution authorizing the Board of Directors, at any time prior to the next annual meeting of shareholders, to implement a share consolidation at a r ...

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that its Board of Directors (the “Board”) has approved its 2026 Financial Strategy and Capital Management Framework, which includes the authorization of a share repurchase program that the management may undertake in value generation conditions. The Board’s d ...

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that its Board of Directors (the “Board”) has approved its 2026 Financial Strategy and Capital Management Framework, which includes the authorization of a share repurchase program that the management may undertake in value generation conditions. The Board’s d ...

CALGARY, AB / ACCESS Newswire / January 6, 2026 / Aurwest Resources Corporation ("Aurwest" or the "Company") (CSE:AWR) is pleased to announce that the Company has entered into a non-binding Letter of Intent with Pacific Bay Minerals Ltd. (TSXV:PBM) whereby Aurwest can earn a 50% interest in Pacific Bay's 100% owned Weaver Gold Project over three years (the "LOI"). ...

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced a significant scientific and manufacturing achievement. Through its investment in PsyLabs, Psyence BioMed has become the first Nasdaq-listed company to produce GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) derived from a naturally extracted ...

With approximately $9.5 million in cash reserves and no debt, the Company is ready to leverage strengthened vertical integration as clinical-grade psilocybin moves into Phase IIb trialsNEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that the Bellberry Human Research Ethics Committee (HREC) has formally app ...

NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that the Bellberry Human Research Ethics Committee (HREC) has formally approved the use of PsyLabs’ psilocybin product (NPX5) in the Company’s ongoing Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for Adjustment Disorder in patients wi ...

Core Insights - Psyence Biomedical Ltd. is positioned as a leader in nature-derived psychedelic therapies, focusing on psilocybin and ibogaine for mental health needs, and has outlined its strategic vision for 2026 in its year-end letter [1][2] Clinical Progress - The company has initiated a Phase IIb clinical trial for psilocybin-assisted psychotherapy targeting Adjustment Disorder in palliative care, with multiple patients dosed across Australian clinical sites [3] - Psyence BioMed ended the year with over USD $9 million in cash reserves and is debt-free, indicating strong financial health [3] Manufacturing and Supply Chain - A multi-million-dollar investment in PsyLabs has enhanced the company's vertical integration, ensuring a GMP-compliant supply of psilocybin and ibogaine for current and future programs [4] - The company achieved a breakthrough in high purity ibogaine production, reinforcing its manufacturing capabilities [4] Regulatory Environment - The Australian Therapeutic Goods Administration's public consultation on psilocybin-assisted therapy for existential distress is a significant regulatory development that aligns with the company's clinical trial efforts [5] Longevity Science Focus - Psyence BioMed is uniquely positioned as the only publicly listed psychedelics company investing in longevity science, emphasizing the emotional and neurobiological aspects of aging [6] 2026 Strategic Outlook - The company plans to accelerate enrollment in its Phase IIb clinical trial, expand its manufacturing footprint, and explore additional longevity-focused indications and strategic partnerships throughout 2026 [6]

Core Insights - Psyence Biomedical Ltd. is the first publicly listed company to investigate the potential impact of psilocybin on longevity, collaborating with researchers in South Africa [1][6] - The initiative aims to explore psilocybin's effects on biological markers associated with aging, which could redefine human longevity and transform aging [1][6] Industry Context - Longevity science is gaining global attention due to aging populations and rising healthcare costs, with public figures like Bryan Johnson promoting psychedelic therapies for longevity [2][6] - Scientific literature supports the intersection of psychedelics and aging biology, with preclinical research indicating that psilocin can extend survival in aged mouse models and increase the lifespan of human cells by over 50% [2] Research Initiative - Psyence BioMed is developing a preclinical protocol to evaluate psilocybin's influence on biological mechanisms related to aging, focusing on biomarkers of cellular stress, inflammation, and mitochondrial function [3] - The research will be led by Dr. Tanya Calvey, a recognized neuroscientist specializing in neuropsychopharmacology, to rigorously investigate the effects of psilocybin on aging [4][5] Strategic Positioning - The initiative complements Psyence BioMed's existing clinical programs, including psilocybin-assisted therapy trials for palliative care patients, advancing the company's mission to explore the therapeutic potential of psilocybin and ibogaine [7] - The company is positioned at the forefront of a new therapeutic arena, with significant interest in understanding how psilocybin may influence biological aging [6]

Core Insights - Curaechoice has partnered with CVS Caremark as its pharmacy benefit manager, aiming to reduce prescription drug costs for its members [1][2] - The collaboration will enable Curaechoice members to access CVS Caremark's extensive network of 65,000 pharmacies starting January 1, 2026 [1] - The partnership is expected to help self-insured employers manage healthcare spending while providing quality care to employees [3] Company Overview - Curaechoice specializes in No-Cost Benefits Optimization, focusing on providing comprehensive healthcare solutions without copays, deductibles, or co-insurance [4] - CVS Caremark, a subsidiary of CVS Health, is recognized for its innovation and affordability in prescription drug delivery, operating a broad network of retail and mail-order locations [4] Market Context - Pharmacy costs account for nearly one-third of an employer's total healthcare spending, highlighting the significance of the partnership in addressing rising healthcare expenses [2] - The collaboration is positioned as a response to the increasing financial pressures faced by families, including costs related to groceries, gas, childcare, and healthcare [3]